Investment
Features
FeesSafety
Academy
More
Pluang+

Sei (SEI) price forecast shows gradual rise to $2.02 by 2032 amid tech upgrades and market factors.

Protocol Fundamentals
19 Oct 2026
Tokenpost
View Source
Neutral
Sei (SEI) price forecast shows gradual rise to $2.02 by 2032 amid tech upgrades and market factors.

Sei (SEI) token price forecasts predict a gradual increase from around $0.08 in 2026 to an average of $1.72 in 2032, with a possible high of $2.02. These projections consider factors like adoption, ecosystem growth, market sentiment, and token vesting but do not guarantee future prices. Sei's recent technical upgrades, including the Eidos storage phase and the Giga upgrade targeting 200,000 transactions per second, aim to enhance network performance but are not direct price drivers. Investors should view these forecasts as estimates, not certainties, given the volatile nature of digital assets.

Sei token price forecasts are discussed here, with Pluang market data provided as context for readers. As of Oct 20, 2026 08:21 WIB, out of 50 major cryptocurrencies priced on Pluang, 16 rose and 33 fell. Notable movers include EOS at Rp12.649 with an 8.13% increase and a typical hold time of 87 days, ZIL at Rp39 with a 5.70% decrease and 58% buy order activity, and SAND at Rp1.029 with a 4.46% decrease and 56% buy order activity. The most notable figure is EOS's 8.13% gain.

More News

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Researchers simulate a 50-qubit quantum computer using NVIDIA's JUPITER, setting a new benchmark in quantum computing.

Researchers simulate a 50-qubit quantum computer using NVIDIA's JUPITER, setting a new benchmark in quantum computing.

The Jülich Supercomputing Centre and NVIDIA used the JUPITER supercomputer to simulate a universal 50-qubit quantum computer, surpassing their previous 48-qubit record from 2019. This full-state simulation required 2,048 TiB of memory, achieved throu...

Protocol Fundamentals
Bullish
4 hours ago
Blackrock files for a Bitcoin ETF that limits losses but caps gains using options and fixed income.

Blackrock files for a Bitcoin ETF that limits losses but caps gains using options and fixed income.

Blackrock has filed with the SEC to launch the Ishares Bitcoin Managed Protection ETF (PBIT), designed to reduce investor losses by using options and fixed-income securities instead of directly holding bitcoin. The ETF aims to limit losses to about 1...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App